Literature DB >> 21147540

Influence of obesity on the incidence and treatment of genitourinary malignancies.

Suzanne Biehn Stewart1, Stephen J Freedland.   

Abstract

BACKGROUND: Obesity is a growing epidemic in the United States. Many genitourinary malignancies are ranked among the current leading causes of cancer. As a result, there has been a surge of interest in understanding the impact of obesity on genitourinary malignancies. We sought to review the current literature concerning the influence of obesity on prostate, kidney, and bladder cancer.
METHODS: A PubMed search was performed using key words related to incidence, treatment, obesity, prostate, kidney, and bladder cancer. Relevant articles and their references were reviewed and utilized.
RESULTS: Obesity appears to promote an increased risk of aggressive prostate cancer (CaP). This may be related, in part, to a detection bias found in obese men. Worse surgical and radiation treatment outcomes in the obese appear to be related not only to technical challenges, but also inherent tumor biology differences and more aggressive disease presentations. A strong association between obesity and increased risk of renal cell carcinoma (RCC) has been established. Laparoscopic radical nephrectomy is now felt to be feasible in the obese and may be a lower morbidity technique compared with open surgery. Interestingly, obesity may confer an improved tumor-specific survival for localized RCC post nephrectomy. The influence of body mass index (BMI) on bladder cancer is poorly understood. Although a relationship may exist, due to the mixed and minimal observations, no firm conclusions should be drawn. Greater perioperative risks following open cystectomy have been found to occur in obese patients secondary to increase technical challenges.
CONCLUSIONS: The relationship between obesity and genitourinary malignancy is impressive. Technical challenges undoubtedly play a role in influencing treatment outcomes. Inherent biological effects are also likely influential. Future research is necessary to delineate these mechanisms and further clarify the influence of obesity on genitourinary cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21147540     DOI: 10.1016/j.urolonc.2009.12.011

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  13 in total

1.  Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Authors:  Ericka M Ebot; Travis Gerke; David P Labbé; Jennifer A Sinnott; Giorgia Zadra; Jennifer R Rider; Svitlana Tyekucheva; Kathryn M Wilson; Rachel S Kelly; Irene M Shui; Massimo Loda; Philip W Kantoff; Stephen Finn; Matthew G Vander Heiden; Myles Brown; Edward L Giovannucci; Lorelei A Mucci
Journal:  Cancer       Date:  2017-07-12       Impact factor: 6.860

2.  Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology.

Authors:  P Pérez-Segura; J E Palacio; L Vázquez; S Monereo; R de Las Peñas; P Martínez de Icaya; C Grávalos; A Lecube; A Blasco; J M García-Almeida; I Barneto; A Goday
Journal:  Clin Transl Oncol       Date:  2017-01-10       Impact factor: 3.405

Review 3.  Metabesity and urological cancers.

Authors:  Ali Atan
Journal:  Turk J Urol       Date:  2017-12-01

4.  Short-term perioperative outcomes of patients treated with radical cystectomy for bladder cancer included in the National Surgical Quality Improvement Program (NSQIP) database.

Authors:  Giorgio Gandaglia; Briony Varda; Akshay Sood; Daniel Pucheril; Ramdev Konijeti; Jesse D Sammon; Shyam Sukumar; Mani Menon; Maxine Sun; Steven L Chang; Francesco Montorsi; Adam S Kibel; Quoc-Dien Trinh
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

5.  Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF.

Authors:  Silas Amâncio Silva; Marina Guimarães Gobbo; Maria Etelvina Pinto-Fochi; Alex Rafacho; Sebastião Roberto Taboga; Eduardo Alves Almeida; Rejane Maira Góes; Daniele Lisboa Ribeiro
Journal:  Int J Exp Pathol       Date:  2014-12-21       Impact factor: 1.925

Review 6.  Clinical management of obese patients with cancer.

Authors:  Wenjing Tao; Jesper Lagergren
Journal:  Nat Rev Clin Oncol       Date:  2013-07-16       Impact factor: 66.675

7.  Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer--evidence of effect modification by prostate size.

Authors:  Jay H Fowke; Saundra Motley; Qi Dai; Raoul Concepcion; Daniel A Barocas
Journal:  Cancer Lett       Date:  2012-10-16       Impact factor: 8.679

8.  A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery.

Authors:  Matthew D Grimes; Michael L Blute; Tyler A Wittmann; Michael A Mann; Kristin Zorn; Tracy M Downs; Fangfang Shi; David F Jarrard; Sara L Best; Kyle A Richards; Stephen Y Nakada; E Jason Abel
Journal:  Urology       Date:  2016-06-23       Impact factor: 2.649

9.  Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer.

Authors:  Michael L Blute; Kristin Zorn; Matthew Grimes; Fangfang Shi; Tracy M Downs; David F Jarrard; Sara L Best; Kyle Richards; Stephen Y Nakada; E Jason Abel
Journal:  BJU Int       Date:  2015-12-22       Impact factor: 5.588

Review 10.  [Influence of obesity on urological malignancies].

Authors:  H Eggers; M A Kuczyk; A J Schrader; S Steffens
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.